Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Natrecor as Nitric Oxide Sparing Agent in Lung Transplantation
NCT00205426Phase 4Completed
- Sponsor
- University of Wisconsin–Madison
- Start
- Aug 2005
- Primary completion
- May 2006
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of nesiritide in pulmonary hypertension (PH) and reperfusion injury (IRI), sponsored by University of Wisconsin–Madison. Primary endpoint: Reduction in nitric oxide used perioperatively. Started Aug 2005; status: completed.
02
Drugs
nesiritide
03
Conditions
pulmonary hypertension (PH)reperfusion injury (IRI)
Beyond the preview
Go deeper on NCT00205426.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00205426.